Clinical Trials Directory

Trials / Sponsors / Calliditas Therapeutics AB

Calliditas Therapeutics AB

Industry · 11 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropa
IgA Nephropathy
Phase 42024-12-17
CompletedA Study to Evaluate Setanaxib in Patients With Alport Syndrome
Alport Syndrome
Phase 1 / Phase 22023-11-27
CompletedEfficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
Primary IgA Nephropathy
Phase 32020-11-17
CompletedStudy to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Femal
Phase 1
Phase 12020-06-24
CompletedComparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets
Phase 1
Phase 12018-12-19
CompletedEfficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
Primary IgA Nephropathy
Phase 32018-09-05
CompletedStudy to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol
Primary Biliary Cirrhosis
Phase 22017-06-26
CompletedSafety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Phase 22013-10-01
CompletedThe Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
Primary IgA Nephropathy
Phase 22012-12-01
CompletedOral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
IGA Nephropathy
Phase 22005-10-01
CompletedEfficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
Post Polio Syndrome, PPS
N/A2001-01-01